Bank of New York Mellon
BEAM icon

Bank of New York Mellon’s Beam Therapeutics BEAM Stock Holding History

Bank of New York Mellon’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5M Buy
362,800
+18,314
+5% +$553K ﹤0.01% 1913
2026
Q1 		$8.21M Sell
344,486
-13,185
-4% -$366K ﹤0.01% 2039
2025
Q4 		$9.91M Sell
357,671
-51,771
-13% -$1.32M ﹤0.01% 1926
2025
Q3 		$9.94M Buy
409,442
+88,325
+28% +$1.76M ﹤0.01% 1928
2025
Q2 		$5.46M Buy
321,117
+3,091
+1% +$53.8K ﹤0.01% 2221
2025
Q1 		$6.21M Buy
318,026
+41,109
+15% +$1.08M ﹤0.01% 2105
2024
Q4 		$6.87M Buy
276,917
+49,372
+22% +$1.26M ﹤0.01% 2127
2024
Q3 		$5.57M Sell
227,545
-60,024
-21% -$1.55M ﹤0.01% 2245
2024
Q2 		$6.74M Sell
287,569
-2,319
-0.8% -$57K ﹤0.01% 2173
2024
Q1 		$9.58M Sell
289,888
-148,517
-34% -$4.63M ﹤0.01% 1976
2023
Q4 		$11.9M Sell
438,405
-55,511
-11% -$1.38M ﹤0.01% 1888
2023
Q3 		$11.9M Buy
493,916
+12,060
+3% +$323K ﹤0.01% 1841
2023
Q2 		$15.4M Buy
481,856
+5,463
+1% +$177K ﹤0.01% 1700
2023
Q1 		$14.6M Sell
476,393
-16,318
-3% -$644K ﹤0.01% 1723
2022
Q4 		$19.3M Sell
492,711
-9,297
-2% -$416K ﹤0.01% 1556
2022
Q3 		$23.9M Buy
502,008
+28,764
+6% +$1.64M 0.01% 1397
2022
Q2 		$18.3M Buy
473,244
+225,868
+91% +$8.98M ﹤0.01% 1578
2022
Q1 		$14.2M Sell
247,376
-2,232
-0.9% -$146K ﹤0.01% 1882
2021
Q4 		$19.9M Buy
249,608
+8,129
+3% +$696K ﹤0.01% 1727
2021
Q3 		$21M Buy
241,479
+26,304
+12% +$2.64M ﹤0.01% 1705
2021
Q2 		$27.7M Buy
215,175
+43,707
+25% +$3.48M 0.01% 1546
2021
Q1 		$13.7M Sell
171,468
-30,496
-15% -$2.9M ﹤0.01% 1918
2020
Q4 		$16.5M Buy
201,964
+56,398
+39% +$2.77M ﹤0.01% 1739
2020
Q3 		$3.58M Buy
145,566
+62,922
+76% +$1.56M ﹤0.01% 2388
2020
Q2 		$2.31M Buy
82,644
+60,223
+269% +$1.3M ﹤0.01% 2593
2020
Q1 		$403K Buy
+22,421
New +$487K ﹤0.01% 3478

Other funds holding BEAM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's BEAM Position: Q2 2026 in Review

Bank of New York Mellon increased its Beam Therapeutics (BEAM) stake by 5.3% in Q2 2026, buying an estimated $553K and bringing the position to 362,800 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1913.

Bank of New York Mellon first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $27.7M in Q2 2021. 109 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Bank of New York Mellon held 362,800 shares of Beam Therapeutics worth $12.5M as of Q2 2026.
  • Bank of New York Mellon bought 18,314 Beam Therapeutics shares in Q2 2026, an estimated $553K.
  • Beam Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1913 holding.
  • Bank of New York Mellon first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Bank of New York Mellon's Beam Therapeutics position peaked at $27.7M in Q2 2021.
  • 109 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.